Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS
Safety of Intraventricular Injection of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Royan Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age:18-65
- both gender
- duration of disease<2 years
- FVC>40% ALS-FRS>26
Exclusion Criteria:
- neurological and psychiatric concomitant disease
- concomitant systemic disease
- treatment with corticosteroid,Ig,immunosuppressive during 12 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: stem cell recipient
The patients who underwent mesenchymal stem cell transplantation.
|
intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
fever
Time Frame: 48hours
|
evaluation the rate of fever 48hours after stem cell injection
|
48hours
|
|
unconsciousness
Time Frame: 6months
|
evaluation the rate of unconsciousness during 6months after stem cell injection.
|
6months
|
|
brain hematoma
Time Frame: 48hours
|
Evaluation the rate of hematoma 48hours after stem cell injection.
|
48hours
|
|
vomiting
Time Frame: 48hours
|
evaluation the rate of vomiting 48hours after stem cell injection.
|
48hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ALS-FRS
Time Frame: 6months
|
evaluation the improvement of ALS-FRS 6months after stem cell injection.
|
6months
|
|
EMG-NCV
Time Frame: 6months
|
evaluation the improvement of EMG-NCV after stem cell injection.
|
6months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Nasser Aghdami, MD,PhD, Head of Royan department of degenerative medicine,Head of Royan celltherapy center
- Study Director: Ali Reza Zali, MD, Head of Neurosurgery research center of Shahid Beheshti University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Royan-Nerve-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.